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Background: Growth hormone secretagogue receptor (GHSR) and its ligand, ghrelin, are important modulators in
weight control and energy homeostasis. Recently, ghrelin is also involved in experimental colitis, but the role of
GHSR in the development of colitis is unclear. The aim was to examine the underlying mechanism of GHSR in IBD
development.
Methods: The temporal expression of GHSR/ghrelin was determined in dextran sulphate sodium (DSS) induced
colitis in Wt mice. The severity of DSS induced colitis from GHSR−/− and WT mice was compared at clinical/
pathological levels. Furthermore, the function of macrophages was evaluated in vivo and in vitro.
Results: Lack of GHSR attenuated colitis significantly at the clinical and pathological levels with reduced colonic
pro-inflammatory cytokines (P < 0.05). This is consistent with the observation of less colonic macrophage infiltration
and TLRs expression from DSS-treated GHSR−/− mice compared to WT mice (P < 0.05). Furthermore, there was
significantly reduced pro-inflammatory cytokines in LPS-stimulated macrophages in vitro from GHSR−/− mice than
WT mice (P < 0.05). Moreover, D-lys3-GHRP6 (a GHSR antagonist) reduced LPS-induced macrophage pro-inflammatory
cytokines from WT mice in vitro.
Conclusions: GHSR contributes to development of acute DSS-induced colitis, likely via elevated pro-inflammatory
cytokines and activation of macrophages. These data suggest GHSR as a potential therapeutic target for IBD.
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Growth hormone secretagogue receptor (GHSR) is a G
protein-coupled receptor with broad distributions in di-
verse tissues. Ghrelin, the ligand of GHSR, is predomin-
ately secreted by the gastrointestinal system. Ghrelin
stimulates the pituitary gland to release growth hormone
(GH) [1] and plays a critical role in maintaining energy
homeostasis and body weight via regulating food intake
[2]. Recent evidence suggests that ghrelin also regulates
immune responses [3,4], with anti-inflammatory proper-
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such as endotoxic shock and gastrointestinal disease [6].
The role of ghrelin/GHSR signaling in the gastrointes-
tinal immunity is controversial, although it has been
demonstrated that ghrelin is anti-inflammatory [3].
Ghrelin increases IL-8 (neutrophil chemotactic factor)
production via activating NF-κB pathway in human
GHSR transgenic colonic epithelial cells [7].
Inflammatory bowel disease (IBD) is a chronic uncon-
trolled inflammation of the intestinal mucosa, which can
be classified into Crohn’s disease (CD) and ulcerative
colitis (UC) [8]. Despite extensive research over decades,
the precise underlying mechanism remains to be fully
understood. It is believed that the pathogenesis of IBD is
associated with the dysregulated immune response to in-
testinal bacterial flora, with contributions from boths is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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recent study reported that the severity of DSS-induced
colitis is attenuated in ghrelin−/− mice, but such attenu-
ation is reversed by exogenous ghrelin [10], which sug-
gests ghrelin is involved in the regulation of IBD.
However the possible role of GHSR in development of
IBD is still not fully understood. Considering the close
biological linkage between ghrelin and GHSR, it is rea-
sonable to hypothesise that GHSR contributes to the
pathogenesis of colitis.
DSS-induced colitis was used to explore the pathogen-
esis of GHSR in colitis, the severity of disease was deter-
mined at both clinical and pathological levels from
GHSR knockout (GHSR−/−) mice and their WT litter-
mates. Furthermore, macrophages are important in
acute DSS-induced colitis [11], and ghrelin is also con-
sidered to regulate the activity of macrophages [12].
Therefore, the production of pro-inflammatory media-
tors by GHSR−/− macrophages following LPS stimulation
was examined in vitro and compared to macrophages
from Wt mice. Finally, the GHSR pathway was validated
by receptor blockade in LPS-stimulated macrophages,
using an antagonist of GHSR, D-lys3-GHRP6 (DLS).
Our study may provide useful data to support the devel-
opment of new therapeutic options for inflammatory
bowel disease.
Results
Temporal expression pattern of GHSR/ghrelin
The temporal expression patterns of GHSR and ghrelin
during DSS challenge were examined in colon, mesen-
teric lymph nodes (MLN) and spleen at 3 time points
(day 0, 4 and 7). Our results demonstrated that GSHR
mRNA expression in MLN or colon, but not spleen,
were increased by ~3 (p < 0.05) or ~1 fold (p < 0.05) at
day 7 DSS challenge, respectively (Figure 1A).
Moreover, there was constitutive level of ghrelin
mRNA in colon, MLN and spleen. Splenic ghrelin
mRNA was induced by ~2 fold (p < 0.01) in MLN at dayFigure 1 Temporal expression patterns of GHSR/ghrelin during acute
solution instead of normal drinking water for 7 days. Mice were sacrificed a
gene expression analysis. The RNA levels of GHSR (A) and ghrelin (B) we
*p < 0.05 and **p < 0.01.7 from DSS-challenged WT mice. However, no obvious
change of ghrelin expression was observed in colon or
spleen following 7 days DSS treatment (Figure 1B).
Lack of GHSR attenuated DSS-induced acute colitis
There was no obvious body weight change or clinical as
well as histopathological abnormalities in mock challenged
GHSR−/− and WT mice, suggesting that deficiency of
GHSR does not cause spontaneous inflammation in the
gastrointestinal system. Significant body weight loss was
observed on days 6 and 7 in DSS challenged GHSR−/− and
WT mice, compared to that of mock challenge (p < 0.05)
(Figure 2A). However there was no significant difference
between WT and GHSR−/− mice with DSS challenge at
any time point. Disease activity index (DAI) score was
used to evaluate the clinical severity of colitis, referring to
three parameters, i.e. body weight loss, diarrhoea and fae-
cal blood as descried previously [13]. The body weight
change was monitored twice day, each group there were 6
mice. Thus the mean and SD of the bodyweight change
were calculated. The DAI score was gradually increased
from day 1 to day 7 in both DSS-treated GHSR−/− and
WT mice. There was significantly higher DAI in WT with
DSS challenge at days 6 (p < 0.01) or 7 (p < 0.05), com-
pared to GHSR−/− mice (Figure 2B), suggesting attenu-
ation of clinical signs in DSS-treated GHSR−/− mice.
Splenic weight at day 7 was measured as it reflects sys-
temic immunity. There was no difference in splenic
weight between WT and GHSR−/− mice without chal-
lenge. A ~2-fold increase of splenic weight was observed
in WT mice with DSS challenge, compared to mock
challenged (p < 0.01), but no significant different splenic
weight was detected in GHSR−/− mice between DSS and
mock treatment. Moreover, splenic weight from DSS-
challenged WT was 40% higher than that of GHSR−/−
mice (p < 0.05) (Figure 2C).
Colon length is an objective macroscopic criteria in
determining severity of colitis [13,14]. No significant dif-
ference in colon length was observed between GHSR−/−colitis induced by DSS. C57/BL6 mice were given 2% DSS aqueous
t day 0, 3, 7 and 11; colons, MLNs and spleens were harvested for
re quantified by rRT-PCR. Each point represents the mean ± SEM;
Figure 2 Symptoms of acute DSS-induced colitis in WT and GHSR−/− mice. Acute colitis was induced in WT and GHSR−/− mice by drinking
2% DSS for 7 days. Body weight change (A) and DAI score (B) which consist of weight loss, diarrhoea and faecal blood was given to each group
daily to monitor the disease development. On day 7, mice were sacrificed, and disease evaluations were given at macroscopic level, including
spleen weights (C) and colon shortening (D). Each point or bar represents the mean ± SEM; NS: no significance, *p < 0.05, **p < 0.01, and ***p < 0.005.
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~25% (p < 0.001) or ~10% (p < 0.05) reduction for the
WT or GHSR−/− mice, respectively, with DSS 7 day
treatment, compared to unchallenged counterparts. In
addition, colon length was significantly shortened in
WT compared to that of GHSR−/− mice following 7 day
DSS challenge (p < 0.05) (Figure 2D).
Histopathology score, including intestinal inflamma-
tion and crypt damage, was applied to determine the se-
verity of colitis, as described [13]. There was no obvious
colonic damage from both GHSR−/− and WT mice with-
out challenge. Severe inflammation was observed in the
colons from both GHSR−/− and WT mice following
7 days DSS treatment, showing epithelial ulceration,
crypt damage, goblet cell loss and infiltration of inflam-
matory cells. Additionally, in agreement with previous
studies [13], the damage/inflammation in transverse/de-
scending colon (Figure 3A, B) was much more severe
than had occurred in the ascending colon (Figure 3C).
Significantly higher histopathological score was ob-
served in transverse (WT: 5.7 ± 0.5, GHSR−/−: 4.5 ± 0.5,
p < 0.05) and descending colons (WT: 7.0 ± 0.5, GHSR
−/−: 4.9 ± 1.0, p < 0.05) from DSS-treated WT, compared
to GHSR−/− mice. However, there was no significant differ-
ence in histopathological score in ascending colon between
DSS-treated WTand GHSR−/− mice (Figure 3A, B, C).Lack of GHSR inhibits the production of cytokines
There was constitutive level of colonic TNF from both
GHSR−/− and WT mice without significant difference, as
measured by tissue ELISA. Colonic TNF was signifi-
cantly upregulated in DSS-challenged WT mice (~2 fold,
p < 0.01), but not GHSR−/− mice, compared to mock
treated mice. Furthermore, colonic TNF was significantly
higher in DSS-challenged WT compared to that of
GHSR−/− mice (p < 0.05) (Figure 4A). A similar pattern
was observed in colonic IL-6 production, which was mark-
edly increased in DSS-challenged WT mice compared to
mock treated WT mice (~2 fold, p < 0.05) or DSS-
treated GHSR−/− mice (~2 fold, p < 0.05) (Figure 4A).
Colonic mRNA levels of TNF, IL-1β, IL-6, IFN-γ, M-
CSF and GM-CSF were quantified, using rRT-PCR.
There were constitutive levels of colonic TNF, IL-1β, IL-
6, IFN-γ, M-CSF and GM-CSF without significant differ-
ence between GHSR−/− and WT mice. The expressions
of TNF, IL-1β, IL-6, M-CSF and GM-CSF were up-
regulated by 11 fold, (p < 0.01), 348 fold (p < 0.05), 2 fold
(p < 0.05), 2 fold (p < 0.05), 2 fold (p < 0.05), respectively
in WT mice following DSS challenge, excepted for and
IFN-γ (no significance). These cytokines were also up-
regulated significantly in GHSR−/− mice following DSS
challenge, but TNF, IL-1β, IL-6, M-CSF or GM-CSF for
GHSR−/− mice were 40%, (p < 0.05), 60%, (p < 0.01), 80%,
Figure 3 Histopathological analysis for the acute DSS-induced colitis in WT and GHSR−/− mice. Colons from DSS-treated WT and GHSR−/−
mice were collected and prepared for H&E staining. The mucosal damage/inflammation in ascending (A), transverse (B) and descending portions
(C) were estimated using a histological scoring system. Each bar represents the mean ± SEM; NS: no significance, * p < 0.05 and *** p < 0.005.
Liu et al. Cell & Bioscience  (2015) 5:12 Page 4 of 10(p < 0.05), 40%, (p < 0.05), 70%, (p < 0.05) lower com-
pared to WT mice following DSS challenge (Figure 4B).
Lack of GHSR decreases TLRs expression
TLR-2 and TLR −4 are two key molecules involved in
triggering innate immunity, which plays an important
role in DSS-induced acute colitis [9,11]. There was a
constitutive level of colonic TLR-2 or TLR-4 expression
for both GHSR−/− and WT mice without significant dif-
ference. The expression of colonic TLR-2/4 was 1.8
(p < 0.05), or 1.5 (p < 0.01) fold increased, respectively, fol-
lowing 7 days DSS challenge in WT mice. However, there
was no obvious change of colonic TLR-2 or TLR-4 for
DSS-challenged GHSR−/− mice; which was significantly
lower than WT expression of TLR-2 (p < 0.01) or −4
(p < 0.005). Moreover, a similar pattern was observed in
MLN expression of TLR-4, but not TLR-2. GHSR−/−
showed a ~40% lower expression of TLR-4 than WT
(p < 0.05) following 7 days DSS challenge (Figure 4C).
Lack of GHSR reduces macrophage infiltration
There was constitutive level of macrophages (F4/80+
cells) in the lamina propria from GHSR−/− and WT mice
without significant difference (Figure 5A and B). Infil-
trating macrophages were recruited substantially in the
inflamed colon following 7 days DSS challenge from
both GHSR−/− and WT mice. Compared to unchal-
lenged, there was a ~5 or ~9 fold increase of colonic F4/
80+ cell infiltration in GHSR−/− (p < 0.01), or WT
(p < 0.005), respectively. The level of infiltrating colonic
macrophages was ~2 fold higher in DSS-treated WT
mice compared to GHSR−/− mice at 7 days treatment.Lack of GHSR suppresses macrophage cytokine
production
There was a constitutive level of TNF in the supernatant
of cultured primary peritoneal macrophages from both
GHSR−/− and WT mice. TNF was induced significantly
in LPS-stimulated macrophages from GHSR−/− and WT
mice (p < 0.005). However, the level of TNF from LPS-
stimulated GHSR−/− macrophages was significantly lower
than that of WT (p < 0.05) (Figure 6A). Additionally, simi-
lar patterns were observed in IL-6 and IL-12 (p40) produc-
tions. The levels of LPS-induced IL-6 or IL-12 (p40) in the
supernatant of macrophages from GHSR−/− mice was re-
duced by ~50% (p < 0.005) and ~35% (p < 0.05) respect-
ively, compared to that of WT mice (Figure 6B, C).
GHSR antagonist alleviates the cytokines released by
macrophages
DLS, an antagonist of GHSR, suppressed the LPS-
stimulated WT macrophage TNF production by ~70%
(p < 0.05) at 100 μM compared to mock treated cells
(Figure 7A). Similarly, it was observed that DLS at 20 or
100 μM reduced IL-12 (p40) by >30% or >40%, respect-
ively (p < 0.05) (Figure 7C). However, no inhibitory func-
tion was observed for IL-6 (Figure 7B).
Discussions
In the current work, we demonstrated that GHSR regu-
lated the development of acute DSS-induced colitis
in vivo and participated in macrophages activation
in vitro. These findings suggest GHSR involvement in
the pathogenesis of IBD.
Figure 4 Productions of pro-inflammatory cytokines and expressions of TLRs. Colons from mock or DSS-treated WT and GHSR−/− mice were
collected, and the production of pro-inflammatory cytokines TNF and IL-6 were detected by ELISA. The final results were expressed as the radio
of cytokine concentration to total protein content (A). Moreover, the RNA levels of TNF, IL-1β, IL-6, M-CSF, GM-CSF and IFN-γ were also examined
in colons (B). Finally, the innate immune receptors of TLR-2 and TLR-4 were quantified in colon and MLN as well respectively (C). Each bar represents
the mean ± SEM; *p < 0.05, **p < 0.01, and ***p < 0.005.
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including various immune organs and cells [3]. In the
current study, the expression of GHSR in colon and MLN
was upregulated following the progression of DSS-
induced colitis, suggesting GHSR contributes to inflam-
matory response in colon. Additionally, ghrelin expression
was also upregulated in MLN, suggesting that GHSR/
ghrelin signaling pathway is important in gastrointes-
tinal mucosal inflammation. These findings are sup-
ported by clinical observations, showing that thecirculating/mucosal ghrelin in IBD patients is signifi-
cantly higher compared to remission and healthy con-
trols [15,16]. This is also consistent with elevated
colonic GHSR expression and the infiltrated numbers
of GHSR+ T cells from active IBD patients [15].
The role of GHSR was further determined in DSS-
induced colitis from GHSR−/− mice and their WT litter-
mates, showing that lack of GHSR significantly ameliorated
the severity of acute DSS-induced colitis at clinical,
macroscopic and microscopic levels, compared to WT
Figure 5 Infiltration of macrophages in DSS-treated WT and
GHSR−/− colons. Colonic infiltrating macrophages were examined
by immunohistochemical staining of F4/80. More F4/80+ cells were
observed in the submucosal region of inflamed WT colon (A) than
GHSR−/− (B). In addition, the numbers F4/80+ cells in the mucosal
and submucosal layer were counted, and the final results were
showed as numbers of F4/80+ cells in per mm2 mucosa (C). Each
bar represents the mean ± SEM; *p < 0.05, **p< 0.01, and ***p< 0.005.
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with a lower spleen weight/size increasing in DSS-
treated GHSR−/− mice, which might be due to lower
systemic inflammation [13,14]. Interestingly, there was
no significant difference in body weight loss between
both genotypes, which might be due to the acuteness of
DSS-induced colitis. Our results demonstrated amelior-
ation of colon shortening in GHSR−/− mice compared
to WT mice following 7 days of DSS challenge, suggest-
ing GHSR plays a key role in the development of acutecolitis. Moreover, these data are also in line with
evidence from histopathology. Our current finding is
supported by others, showing that absence of ghrelin
attenuates DSS-induced colitis, and exogenous treat-
ment with ghrelin enhances the manifestations of dis-
ease [10].
IBD is one of the fields where the immune regulatory
effect of ghrelin/GHSR is of considerable relevance.
DSS-induced acute colitis mainly relates to innate im-
munity [9,11], and TLRs play an important role in innate
immunity. Exaggerated TLR signaling might contribute
to pathogenesis of IBD [17]. The present study demon-
strated that colonic and MLN expression of TLR-2 or
TLR-4 in DSS treated GHSR−/− mice was significantly
lower than that of WT. This observation suggests that
GHSR contributes to colonic inflammation via regulat-
ing TLRs mediated innate immunity.
The profile of pro-inflammatory cytokines is a general
standard that reflects colonic inflammatory status of IBD
patients and animal colitis models. In the present study,
we observed reduced colonic pro-inflammatory cytokines
both at protein and RNA levels from DSS-challenged
GHSR−/− mice compared to that of WT. This observation
further supports the important role of GHSR in colonic
inflammation.
Furthermore, M-CSF/GM-CSF are critical modulators
in regulating myeloid cells proliferation, maturation and
recruitment, which might implicate them in the patho-
genesis of IBD [18]. M-CSF gene deficiency or blockage
attenuates DSS-induced colitis, accompanied with less
infiltration of immune cells [19,20]. Our data showed
that M-CSF and GM-CSF were also lower expressed in
DSS-treated GHSR−/− mice, compared to that of WT.
This is also consistent with reduced colonic macrophage
infiltrations in DSS-challenged GHSR−/− than WT. GM-
CSF contributes to neutrophil accumulation and priming
in IBD [21], with elevated GM-CSF in mucosal lesions
from IBD patients and mice colitis models [13,21]. We
have demonstrated that colonic GM-CSF expression was
significantly induced in DSS-treated WT mice, but not
GHSR−/−, compared to that of mock challenge, suggest-
ing that GHSR mediated colonic inflammation might be
via M-CSF and GM-CSF.
Additionally, significantly reduced pro-inflammatory
cytokines [TNF, IL-6 and IL-12 (p40)] were observed in
LPS-stimulated macrophages from GHSR−/− mice com-
pared to WT in vitro, suggesting GHSR plays a key role
in macrophage activation. This is also confirmed by the
finding that DLS, a GHSR antagonist, suppressed LPS-
induced pro-inflammatory cytokine releases in macro-
phages from WT mice.
In the current work, we found that GHSR regulates
immune reaction. However, exogenous ghrelin is consid-
ered as an anti-inflammatory modulator in vitro and
Figure 6 LPS-induced pro-inflammatory cytokine productions in macrophages from WT and GHSR−/− mice. The primary peritoneal
macrophages from WT and GHSR−/− mice were isolated and stimulated with LPS for 2 hours. The productions of pro-inflammatory cytokines, TNF
(A), IL-6 (B) and IL-12 (p40) (C), were detected in the supernatants by ELISA. Each bar represents the mean ± SEM; *p < 0.05 and ***p < 0.005.
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dogenous and exogenous conditions and/or different
animal models. Moreover, ghrelin is an important hor-
mone with various functions on other systems, e.g.
stimulating GH/IGF-1 axis and gut motility [22,23],
which might also contribute to the pathogenesis of IBD
[22,24]. In addition, the role of ghrelin/GHSR in intes-
tinal epithelium might be pro-inflammatory, as IL-8 is
up-regulated in GHSR over-expressing colonic epithelial
cells with ghrelin stimulation [7].Conclusions
In summary, gastrointestinal GHSR and ghrelin were in-
duced in response to DSS stimulation. DSS-induced colitis
was ameliorated in GHSR−/− mice compared to WT. The
possible mechanism may be mediated by inhibiting innate
immunity, leading to a reduction of pro-inflammatory
cytokine productions and a decrease of local macrophage
infiltration in vivo and in vitro. Our data demonstrated
that GHSR contributes to the development of DSS-Figure 7 Effect of GHSR antagonist on LPS-induced pro-inflammato
C57/BL6 primary peritoneal macrophages were isolated and stimulated w
administrated to cells 24 hours before LPS stimulation. The productions of TN
ELISA. Each bar represents the mean ± SEM; NS: no significance, *p < 0.05 andinduced colitis, and suggest GHSR as a potential thera-
peutic target for IBD.Materials and methods
Animals
In the experiment of temporal expression patterns,
8 week-old male C57/BL6 mice were selected. For
DSS-induced colitis, GHSR−/− mice and their WT lit-
termates were generated as described previously [25].
All animals were supplied by Shanghai Research
Centre for Model Organisms and housed under specific
pathogen-free environment with food and water ad
libitum. The environment was maintained at 22°C
with a 12 h light/dark cycle. Animal welfare and ex-
perimental procedures were carried out strictly in ac-
cordance with the guidance for care and use of
laboratory animals (National Research Council of
USA, 1996) and approved by Institutional Animal
Care and Use Committee of Shanghai Research Centre
for Model Organisms.ry cytokine productions in macrophages from C57/BL6 mice.
ith LPS for 2 hours. Two doses of DLS (20 and 100 μM) were
F (A), IL-6 (B) and IL-12 (p40) (C), were detected in the supernatants by
***p < 0.005.
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Mice were customised environment one week in the
animal house prior to DSS challenge. Acute colitis was
induced by giving 2% DSS (MW: 36 ~ 50 k; MP
Biomedicals, Australia) in normal drinking water for
7 days as described previously [13]. Mice were allowed
free access to water and food during experiments.
For temporal expression pattern analysis, C57/BL6
mice were sacrificed at 0, 4 and 7 days post DSS chal-
lenge (n = 3 for each time point). The colon, mesenteric
lymph node (MLN) and spleen were collected and snap
frozen in liquid nitrogen.
For determining the role of GHSR in the development
of colitis, body weight and fecal score (consistency and
stool blood) were determined daily post DSS challenge
in both GHSR−/− and WT mice (control: n = 8, DSS: n =
11). Body weight change of animals from different geno-
types/treatments was expressed as percent body weight
gain/loss, in comparison with day 0. Disease activity
index (DAI) [14] consists of the following parameters:
body weight loss (0 ~ 4), stool consistency (0 ~ 4) and
fecal blood (0 ~ 4) were monitored. Colons and MLN
were collected at day 7 post DSS challenge, and the
lengths of colon and weights of spleen were measured.
For understanding the experimental procedures, a flow
diagram was provided in the Additional file 1: Figure S1.
Histological assessment
Colons were harvested from GHSR−/− mice and their
WT littermates, as “Swiss roll” [26]. The rolls were fixed
in 4% paraformaldehyde over night for tissue processing
and wax embedding. The colon was sectioned (5 μm)
for haematoxylin and eosin (H&E) staining and
immunohistochemistry.
Histopathology was scored by an independent patholo-
gist, as described previously [13]. Two independent pa-
rameters were measured: the extent of inflammation (0,
none; 1, slight; 2, moderate; 3, severe; 4, massive) and
the extent of crypt damage (0, none; 1, the basal one-
third portion damaged; 2, the basal two-thirds portion
damaged; 3, the entire crypt damaged but the surface
epithelium intact; 4, the entire crypt and epithelium
lost). The three portions of colon (ascending, transverse
and descending colon) were scored respectively.
Immunohistochemistry for macrophages
For macrophages identification, immunohistochemical
staining of F4/80 (1:400, Abcam, USA) was processed as
described previously [13], which is a broadly used cell
marker for macrophages. The binding of the primary anti-
body was detected with a biotin-conjugated secondary
antibody (1:200, Biolegend, USA) followed by a
streptavidin-HRP reaction. Diaminobenzidine (DAB) was
used as the immunodetection substrate.Colonic cytokines determination
Colon samples were homogenised in RIPA lysate (Thermo
Fisher Scientific, USA), and the supernatant was collected
for assessments of pro-inflammatory cytokines (n = 4 for
each group). TNF and IL-6 were detected using the com-
mercial ELISA kits (Biolegend, USA), according to the in-
struction from the manufacturer. The final results were
represented as the ratio of cytokine concentration to total
protein content, which was determined using a BCA re-
agent kit (Beyotime Institute of Biotechnology, China).
Gene expression analysis
The temporal expressions of GHSR/ghrelin responding
to DSS challenge were detected in colon, MLN and
spleens, respectively. Moreover, colon and MLN from
mock or DSS-challenged GHSR−/− and WT mice, were
harvested for detecting the RNA levels of TNF, IL-1β,
IL-6, IFN-γ, M-CSF, GM-CSF, TLR-2 and TLR-4. Total
RNA in tissue samples was isolated using Trizol (Roche
Diagnostics, Germany) and reverse transcribed by an
iScript cDNA Synthesis Kit (Bio-Rad, USA). The gene
expressions were quantified by rRT-PCR, using an iQ
SYBR Green Supermix (Bio-Rad, USA) and a gradient
cycler machine (Eppendorf, Hamburg, Germany). β-
actin was chosen as the reference gene. Data was repre-

































(reverse).Isolation of peritoneal macrophages and stimulation with
LPS
Peritoneal macrophages from GHSR−/− and WT mice
were collected as described before [27]. In brief, cells
were harvested via peritoneal lavage with 5 ml RPMI
1640 medium (Invitrogen, USA). Red blood cells were
removed by red blood lysis buffer (Beyotime Institute of
Biotechnology, China), and the peritoneal cells were
seeded into a 12-well plate at 2 × 106 cells/well and incu-
bated at 37°C with 5% CO2 for 2 hours. After removing
non-adherent cells by washing twice with PBS, the ad-
herent macrophages were supplemented with fresh
RPMI 1640 medium containing 10% fetal calf serum
(FCS).
Activation of macrophage was induced by 100 ng/ml
LPS (Sigma-Aldrich, USA) for 2 hours incubation. Fur-
thermore, to confirm whether GHSR is involved in the
function of macrophage, peritoneal macrophages were
collected from C57/BL6 mice, and given DLS (Bachem,
UK) at 20 or 100 μM after LPS 24 hour stimulation. The
levels of TNF, IL-6 and IL-12 (p40) in culture superna-
tants were determined by ELISA kits (Biolegend, USA).Statistical analyses
All data are shown as mean ± SEM. Differences between
groups were estimated using one-way or two-ways ana-
lysis of variance (ANOVA), followed by the Bonferroni
posttest analysis. Significant differences were accepted
when p values <0.05. The statistic analysis was calculated
and plotted using GraphPad Prism version 4.0 (Graph-
Pad Software, Canada).Additional file
Additional file 1: Figure S1. The diagram demonstrated the experimental
procedure.
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